CRMPs: Critical molecules for neurite morphogenesis and neuropsychiatric diseases

T. T. Quach, J. Honnorat, P. E. Kolattukudy, Rajesh Khanna, A. M. Duchemin

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Neuronal polarity and spatial rearrangement of neuronal processes are central to the development of all mature nervous systems. Recent studies have highlighted the dynamic expression of Collapsin-Response-Mediator Proteins (CRMPs) in neuronal dendritic/axonal compartments, described their interaction with cytoskeleton proteins, identified their ability to activate L-and N-type voltage-gated calcium channels (VGCCs) and delineated their crucial role as signaling molecules essential for neuron differentiation and neural network development and maintenance. In addition, evidence obtained from genome-wide/genetic linkage/proteomic/translational approaches revealed that CRMP expression is altered in human pathologies including mental (schizophrenia and mood disorders) and neurological (Alzheimer's, prion encephalopathy, epilepsy and others) disorders. Changes in CRMPs levels have been observed after psychotropic treatments, and disrupting CRMP2 binding to calcium channels blocked neuropathic pain. These observations, altogether with those obtained from genetically modified mice targeting individual CRMPs and RNA interference approaches, pave the way for considering CRMPs as potential early disease markers and modulation of their activity as therapeutic strategy for disorders associated with neurite abnormalities.

Original languageEnglish (US)
Pages (from-to)1037-1045
Number of pages9
JournalMolecular Psychiatry
Volume20
Issue number9
DOIs
StatePublished - Sep 24 2015

Fingerprint

Semaphorin-3A
Neurites
Morphogenesis
Proteins
Calcium Channels
Genetic Linkage
Aptitude
Prions
Brain Diseases
Neuralgia
RNA Interference
Cytoskeleton
Mood Disorders
Mental Disorders
Proteomics
Nervous System
Epilepsy
Schizophrenia
Maintenance
Genome

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

CRMPs : Critical molecules for neurite morphogenesis and neuropsychiatric diseases. / Quach, T. T.; Honnorat, J.; Kolattukudy, P. E.; Khanna, Rajesh; Duchemin, A. M.

In: Molecular Psychiatry, Vol. 20, No. 9, 24.09.2015, p. 1037-1045.

Research output: Contribution to journalArticle

Quach, TT, Honnorat, J, Kolattukudy, PE, Khanna, R & Duchemin, AM 2015, 'CRMPs: Critical molecules for neurite morphogenesis and neuropsychiatric diseases', Molecular Psychiatry, vol. 20, no. 9, pp. 1037-1045. https://doi.org/10.1038/mp.2015.77
Quach, T. T. ; Honnorat, J. ; Kolattukudy, P. E. ; Khanna, Rajesh ; Duchemin, A. M. / CRMPs : Critical molecules for neurite morphogenesis and neuropsychiatric diseases. In: Molecular Psychiatry. 2015 ; Vol. 20, No. 9. pp. 1037-1045.
@article{141085af85564eb4be7d85e12fbb75d4,
title = "CRMPs: Critical molecules for neurite morphogenesis and neuropsychiatric diseases",
abstract = "Neuronal polarity and spatial rearrangement of neuronal processes are central to the development of all mature nervous systems. Recent studies have highlighted the dynamic expression of Collapsin-Response-Mediator Proteins (CRMPs) in neuronal dendritic/axonal compartments, described their interaction with cytoskeleton proteins, identified their ability to activate L-and N-type voltage-gated calcium channels (VGCCs) and delineated their crucial role as signaling molecules essential for neuron differentiation and neural network development and maintenance. In addition, evidence obtained from genome-wide/genetic linkage/proteomic/translational approaches revealed that CRMP expression is altered in human pathologies including mental (schizophrenia and mood disorders) and neurological (Alzheimer's, prion encephalopathy, epilepsy and others) disorders. Changes in CRMPs levels have been observed after psychotropic treatments, and disrupting CRMP2 binding to calcium channels blocked neuropathic pain. These observations, altogether with those obtained from genetically modified mice targeting individual CRMPs and RNA interference approaches, pave the way for considering CRMPs as potential early disease markers and modulation of their activity as therapeutic strategy for disorders associated with neurite abnormalities.",
author = "Quach, {T. T.} and J. Honnorat and Kolattukudy, {P. E.} and Rajesh Khanna and Duchemin, {A. M.}",
year = "2015",
month = "9",
day = "24",
doi = "10.1038/mp.2015.77",
language = "English (US)",
volume = "20",
pages = "1037--1045",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - CRMPs

T2 - Critical molecules for neurite morphogenesis and neuropsychiatric diseases

AU - Quach, T. T.

AU - Honnorat, J.

AU - Kolattukudy, P. E.

AU - Khanna, Rajesh

AU - Duchemin, A. M.

PY - 2015/9/24

Y1 - 2015/9/24

N2 - Neuronal polarity and spatial rearrangement of neuronal processes are central to the development of all mature nervous systems. Recent studies have highlighted the dynamic expression of Collapsin-Response-Mediator Proteins (CRMPs) in neuronal dendritic/axonal compartments, described their interaction with cytoskeleton proteins, identified their ability to activate L-and N-type voltage-gated calcium channels (VGCCs) and delineated their crucial role as signaling molecules essential for neuron differentiation and neural network development and maintenance. In addition, evidence obtained from genome-wide/genetic linkage/proteomic/translational approaches revealed that CRMP expression is altered in human pathologies including mental (schizophrenia and mood disorders) and neurological (Alzheimer's, prion encephalopathy, epilepsy and others) disorders. Changes in CRMPs levels have been observed after psychotropic treatments, and disrupting CRMP2 binding to calcium channels blocked neuropathic pain. These observations, altogether with those obtained from genetically modified mice targeting individual CRMPs and RNA interference approaches, pave the way for considering CRMPs as potential early disease markers and modulation of their activity as therapeutic strategy for disorders associated with neurite abnormalities.

AB - Neuronal polarity and spatial rearrangement of neuronal processes are central to the development of all mature nervous systems. Recent studies have highlighted the dynamic expression of Collapsin-Response-Mediator Proteins (CRMPs) in neuronal dendritic/axonal compartments, described their interaction with cytoskeleton proteins, identified their ability to activate L-and N-type voltage-gated calcium channels (VGCCs) and delineated their crucial role as signaling molecules essential for neuron differentiation and neural network development and maintenance. In addition, evidence obtained from genome-wide/genetic linkage/proteomic/translational approaches revealed that CRMP expression is altered in human pathologies including mental (schizophrenia and mood disorders) and neurological (Alzheimer's, prion encephalopathy, epilepsy and others) disorders. Changes in CRMPs levels have been observed after psychotropic treatments, and disrupting CRMP2 binding to calcium channels blocked neuropathic pain. These observations, altogether with those obtained from genetically modified mice targeting individual CRMPs and RNA interference approaches, pave the way for considering CRMPs as potential early disease markers and modulation of their activity as therapeutic strategy for disorders associated with neurite abnormalities.

UR - http://www.scopus.com/inward/record.url?scp=84940439562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940439562&partnerID=8YFLogxK

U2 - 10.1038/mp.2015.77

DO - 10.1038/mp.2015.77

M3 - Article

C2 - 26077693

AN - SCOPUS:84940439562

VL - 20

SP - 1037

EP - 1045

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 9

ER -